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University Medical Centre Groningen, Department of Gynaecologic Oncology, Groningen, The NetherlandsThe sentinel-node procedure was introduced in cancer
therapy in order to reduce the morbidity that is associated
with full lymphadenectomy without compromising survival
rates. In gynaecological cancer the application of the senti-
nel-node procedure has been investigated in vulvar, cervical,
and endometrial cancer.
In vulvar cancer, the Groningen International Study on
Sentinel nodes in Vulvar cancer (GROINSS-V) showed that it
was safe to omit inguinofemoral lymphadenectomy in pa-
tients with a negative sentinel node. Eligible patients who
underwent the procedure had unifocal squamous-cell cancer
of the vulva, with a maximum diameter of 4 cm and no suspi-
cious groin nodes at palpation. In the case of a negative sen-
tinel node, no inguinofemoral lymphadenectomy was
performed, and patients were followed up regularly. Both
short-term and long-term treatment-related morbidities were
significantly lower when only the sentinel node was removed.
Groin recurrences were observed in 2.3% of the patients with
a negative sentinel node [1]. An analysis of the patients with a
positive sentinel node showed an increasing risk for involve-
ment of non-sentinel nodeswith increasing size of themetas-
tasis in the sentinel node. Furthermore, the prognosis was
significantly worse for patients with sentinel-node metasta-
ses >2 mm [2]. More recently Levenback and colleagues
published the results of the Gynaecologic Oncology Group
study on the sentinel node procedure in vulvar cancer
(GOG-173). They included 452 patients; all patients underwent
inguinofemoral lymphadenectomy after sentinel-node detec-
tion. They found a false-negative predictive value of 3.7%. In
women with a tumour <4 cm, the false-negative predictive
value was 2.0%, a result resembling that of GROINSS-V [3]. Pit-
falls of the sentinel-node procedure are gross nodal involve-
ment that may obstruct lymph flow and thereby cause
bypassing of the sentinel node and confusion about the num-
ber of sentinel nodes [4]. Preoperative groin imaging with
computed tomography (CT), magnetic resonance imaging
(MRI) or ultrasound (US) is mandatory to exclude gross nodal
involvement, while preoperative lymphoscintigraphy givesadequate information on the number of sentinel nodes per
groin and presence of unilateral or bilateral sentinel nodes.
Controversies remain regarding the method of preoperative
imaging, the therapeutic benefit of inguinofemoral lymphad-
enectomy in case of micrometastases in the sentinel node,
and alternative treatment options in patients with a positive
sentinel node. An ongoing second observational study, GRO-
INSS-V-II, is investigating the safety of radiotherapy instead
of inguinofemoral lymphadenectomy in patients with a posi-
tive sentinel node. Preoperative imaging is mandatory in this
study to exclude gross nodal involvement. The GOG has
joined GROINSS-V-II; this international collaboration will help
shorten the duration of studies in rare malignancies like
vulvar cancer.
In cervical cancer single-institution case series had
already demonstrated the feasibility of the sentinel-node
concept, when Altgassen and colleagues in 2008 published
the results of their multicentre study on the detection rate
and diagnostic accuracy. The detection rate of pelvic senti-
nel nodes was 88.6% in 590 patients. They also showed a
significantly higher detection rate when blue dye and a
radioactive tracer were combined. The sensitivity was
77.4% overall, but 90.9% in women with tumours 62 cm.
They concluded that the sensitivity of the sentinel-node
concept was low, but that patients with tumours 62 cm
might profit from this concept [5]. The results of the SENTI-
COL study, by Le´curu and colleagues, showed that in 139
stage IA1 with LVSI-IB1 cervical cancer patients the senti-
nel-node procedure yielded a sensitivity of 92.0% and a neg-
ative predictive value (NPV) of 98.2% for detection of nodal
metastasis. No false-negative results were observed in those
patients in whom the sentinel node was identified bilater-
ally. They concluded that the sentinel-node procedure has
a high sensitivity and NPV, and is especially reliable in pa-
tients in whom the sentinel node is detected bilaterally [6].
These results were confirmed in a recent study by Cibula
and colleagues in their study in 645 patients [7]. The same
authors showed that the presence of micrometastases iniversity of
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tion in overall survival, which was equivalent to that in pa-
tients with macrometastasis. No prognostic significance was
found for isolated tumour cells [8]. Recently a single-institu-
tion study showed that when comparing a prospectively
collected patient cohort (in whom a pelvic lymphadenec-
tomy was omitted in the case of a negative sentinel node)
with historic controls in whom a full lymphadenectomy
was performed, the sentinel-node technique yielded a
higher proportion of patients with lymph-node metastases,
indicating a higher sensitivity of the sentinel-node tech-
nique [9]. However, the clinical impact of sentinel-node
biopsy in cervical cancer needs to be further evaluated in
observational or preferably randomised studies comparing
sentinel-node biopsy with sentinel-node biopsy plus
lymphadenectomy (NCT01157962).
Finally, in endometrial cancer the sentinel-node procedure
is still in a preliminary stage of evaluation. Different tech-
niques of tracer injection have been proposed; however, there
is no consensus about the most accurate method for identify-
ing the sentinel node. Cervical and intramyometrial subsero-
sal injections are safe and simple, but probably do not reflect
the expected endometrial cancer lymphatic drainage. Also
the detection rate is low. Hysteroscopical injection might bet-
ter reproduce the drainage of the tumour; however, this is
complex, costly, and also shows a high variability in detection
rate. Different studies showed identification rates varying
from 45% to 100% [10]. Recently transvaginal ultrasound-
guided myometrial injection of the radioactive tracer was
suggested as a safe, feasible method for sentinel-node
detection [11].
In conclusion, GROINSS-V and GOG173 have provided ade-
quate evidence for the safety of sentinel-node detection in se-
lected early-stage vulvar cancer patients. The sentinel-node
procedure is now part of standard therapy in vulvar cancer
patients with a unifocal tumour <4 cm with no palpable
lymph nodes. Only in the hands of an experienced multidisci-
plinary team should the procedure be considered safe. In cer-
vical cancer, the sentinel-node procedure seems a promising
tool, especially in patients with tumours 62 cm and when
bilateral drainage is found. The results of a large randomised
trial comparing sentinel-node biopsy to sentinel-node biopsy
plus lymphadenectomy are expected in a few years. In endo-
metrial cancer, studies are still evaluating the best diagnostic
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